The MammaPrint test is a genomic test that analyzes the activity of a group of 70 genes from a breast cancer tissue sample that can affect how a cancer is likely to behave and respond to treatment.
In the United States, MammaPrint can be used to analyze early-stage breast cancers that are:
- stage I or stage II
- smaller than 5 centimeters
In the rest of the world, MammaPrint can be used on cancers that are:
- stage I or stage II
- smaller than 5 centimeters
- in three or fewer lymph nodes
In both the United States and internationally, MammaPrint can be used to analyze cancers that are hormone-receptor-positive and hormone-receptor-negative.
The MammaPrint test calculates whether the cancer has a low or high risk of coming back (recurring) within 10 years after diagnosis. Knowing if a cancer has a low or high risk of recurrence could help women and their doctors decide if chemotherapy or other treatments are needed after surgery -- called adjuvant treatments -- to reduce recurrence risk.
A study suggests the MammaPrint test can accurately decide which women can safely skip chemotherapy after surgery.
The research was presented on April 18, 2016 at the American Association for Cancer Research Annual Meeting. Read the abstract of “Primary analysis of the EORTC 10041/BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.”
There are several other genomic tests used to analyze breast cancer, including the Oncotype DX test. Because the Oncotype DX test has been validated by much research, right now it is the most widely used genomic test for breast cancer. The study summarized here suggests that the MammaPrint eventually also may be widely used to make decisions about treatments after surgery.
This study was a randomized, prospective study, which means that a large group of people were randomly assigned to one thing or another and then the researchers watched for the outcomes over a long period of time. A prospective study is stronger than a retrospective study, which looks at data collected before the study was designed.
The study included 6,693 women from nine countries diagnosed with early-stage breast cancer who had surgery. At first, the study only enrolled women diagnosed with cancer that hadn’t spread to the lymph nodes (node-negative disease). But after the MammaPrint test was validated for use in women with up to three positive nodes, the study requirements were changed to include women diagnosed with early-stage disease with zero to three positive nodes.
Each woman’s risk of recurrence within 10 years of diagnosis was estimated with two different tests:
- the MammaPrint test
- a computer program that analyzes the clinical characteristics of the cancer, including size, grade, hormone receptor status, and HER2 status
Women diagnosed with hormone-receptor-positive disease who were estimated to have an 88% or higher chance of being alive 10 years after diagnosis by the computer program, with no chemotherapy or hormonal therapy, were considered “clinical low risk.” Women diagnosed with hormone-receptor-negative disease who were estimated to have a 92% or higher chance of being alive 10 years after diagnosis by the computer program, with no chemotherapy, also were considered “clinical low risk.”
Women considered to have a low risk of recurrence based on BOTH the MammaPrint test and the computer program were not treated with chemotherapy after surgery.
Women considered to have a high risk of recurrence based on the results of both tests were treated with chemotherapy.
Women who had what the researchers called “discordant results” -- meaning one test estimated a high risk of recurrence and the other test estimated a low risk of recurrence -- were treated with radiation therapy after surgery. The researchers then randomly chose one test result to decide if the women would be treated with chemotherapy.
The researchers wanted to see if women who didn’t get chemotherapy because the MammaPrint test estimated low recurrence, even though the computer program estimated high risk, had similar survival rates to women with the same risk estimates who were treated with chemotherapy.
"Our hypothesis was that the MammaPrint genomic assay would outperform the clinical criteria by reducing the prescription of adjuvant chemotherapy without impairing patient outcomes," said Marine Piccart, M.D., of the Jules Bordet Institute in Brussels, who presented the study. Dr. Piccart also is a member of the Breastcancer.org Professional Advisory Board.
The characteristics of the women with discordant results:
- 80% had node-negative disease
- 58% had cancers that were 2 centimeters or smaller in size
- 88% had estrogen-receptor-positive cancer
- 10% had HER2-positive cancer
After about 5 years of follow-up, distant metastasis-free survival was:
- 97.6% for women with estimated low risk by both the computer program and the MammaPrint test
- 90.6% for women with estimated high risk by both the computer program and the MammaPrint test
- 94.4% for women with estimated high risk by the computer program/low risk by MammaPrint who did not receive chemotherapy
- 95.9% for women with estimated high risk by the computer program/low risk by MammaPrint who were treated with chemotherapy
- 95.0% for women with estimated low risk by the computer program/high risk by MammaPrint who did not receive chemotherapy
- 95.8% for women with estimated low risk by the computer program/high risk by MammaPrint who were treated with chemotherapy
Distant metastasis-free survival is living without the cancer coming back in a part of the body away from the breast.
So women who were determined to have a low risk of recurrence by the MammaPrint test had about the same distant recurrence rates, no matter whether they were treated with chemotherapy or not. This suggests the MammaPrint test could be used to help decide which women diagnosed with early-stage disease could avoid chemotherapy after surgery.
If you’ve been diagnosed with early-stage breast cancer and are weighing the pros and cons of adding chemotherapy to your treatment plan, the MammaPrint test may help you and your doctor make that decision. Besides any genomic test results, you and your doctor will consider other factors when developing your treatment plan, such as:
- your age
- the size of the cancer
- hormone receptor protein levels
- the grade of the cancer
- any other health conditions you have
- your personal preferences
Together, you can make the best treatment decisions for YOU!
You can learn more on the Breastcancer.org MammaPrint Test page.
Can we help guide you?
Create a profile for better recommendations
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....
Breast Cancer Stages
The stage of a breast cancer is determined by the cancer’s characteristics, such as how large it...